Concepedia

Consolación Moltó

CM

6

Publications

194

Citations

6

H-Index

2017

Active since

Affiliations

Hospital de Sant Pau(Current)

Universitat Autònoma de Barcelona

Harvard University

Brigham and Women's Hospital

University of Toronto

Consolación Moltó is an author at Hospital de Sant Pau specializing in cancer therapeutics, drug development, and pre-clinical pharmacology.

Top concepts

Publications per year

2017–2025

6

Publications

6

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

Ariadna Tibau, Consolación Moltó, Alberto Ocaña et al. · JNCI Journal of the National Cancer Institute · 2017 · 85 citations · Full text

Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials

Daniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser et al. · Journal of Clinical Oncology · 2018 · 39 citations

, , +22

Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

Consolación Moltó, Thomas J. Hwang, María Borrell et al. · Cancer · 2020 · 32 citations · Full text

Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies

Ariadna Tibau, Thomas J. Hwang, Consolación Moltó et al. · JAMA Oncology · 2024 · 15 citations · Full text

Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA

Ariadna Tibau, Thomas J. Hwang, Alejandra Romano et al. · JAMA Network Open · 2025 · 13 citations · Full text

Rows per page

1–5 of 6